The Sunnyvale, Calif.-based firm said it expects second-quarter revenue to come in at $575 million, against a $630 million consensus, according to CNBC.  "While we are disappointed in our performance this quarter," CEO Gary Guthart said in a statement, "particularly with respect to our capital sales in the U.S., overall procedure performance was solid in a difficult environment. We remain confident in the value that our products and services bring to patients, hospitals and the healthcare system."  Here's the full release » FREE AppDownload
